ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. on behalf of long-term stockholders following a class action complaint filed on March 19, 2024, concerning the period from March 22, 2022 to December 21, 2023 [2][7] - The investigation focuses on whether AlloVir's board of directors breached their fiduciary duties to the company [2] - The complaint alleges that AlloVir made materially false and misleading statements regarding its business and operations, particularly concerning the posoleucel Phase 3 studies [7] Company Details - AlloVir announced on December 22, 2023, that it would discontinue the posoleucel Phase 3 studies due to efficacy concerns, stating that pre-planned analyses indicated they would not meet their primary endpoints [7] - Following this announcement, AlloVir's stock price fell by $1.57 per share, or 67.38%, closing at $0.76 per share on December 22, 2023 [7]